Quantitative analysis of the impact of neovascular age-related macular degeneration (AMD) on the UK population has led a team of researchers to call for urgent, early access to the new class of drug therapies for the disease.
US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema
Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars
Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel
The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections
MACUSTAR receives additional EMA support for AMD clinical study
The scientific outputs from MACUSTAR’s study could impact more than 200 million patients with AMD globally